Innovative drug approvals vs Antibody-drug conjugate trial starts in China
In 2025, innovative drug approvals in China stood at 76, against 177 for antibody-drug conjugate trial starts.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Innovative drug approvals and Antibody-drug conjugate trial starts
Unit: count · 8 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Innovative drug approvals | 2025 | Actual | 76 |
| Innovative drug approvals | 2024 | Actual | 48 |
| Antibody-drug conjugate trial starts | 2025 | Actual | 177 |
| Antibody-drug conjugate trial starts | 2024 | Actual | 150 |
| Antibody-drug conjugate trial starts | 2023 | Actual | 120 |
| Antibody-drug conjugate trial starts | 2022 | Actual | 69 |
| Antibody-drug conjugate trial starts | 2021 | Actual | 40 |
| Antibody-drug conjugate trial starts | 2020 | Actual | 25 |
Shared periods
Side by side
2 periods are published for both series in China as annual figures on the same basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from
Innovative drug approvals
Total number of innovative pharmaceutical products granted regulatory marketing authorization.
2 observations charted in China · source organisations: MOFCOM
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in China · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring